NeurAxis, Inc.
AMEX:NRXSBiotechnology
Healthcare
$4.87 +4.25%
+$0.29 today
- Market cap
- $69.12M
- Beta
- 1.41
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$0.67
52W Low $2.20High $9.33
Volume 0.23M
Average 0.18M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$6.43M
FY 2025 · Annual
Investing Cash Flow
-$131,150.00
FY 2025 · Annual
Financing Cash Flow
$7.83M
FY 2025 · Annual
-19.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (3.03M) | (4.78M) | (14.63M) | (8.24M) | (7.8M) |
| Depreciation & Amortization | 36.71K | 37.13K | 40.73K | 37.83K | 59.5K |
| Deferred Income Tax | 41.11K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 48.64K | 27.32K | 750K | 1.4M | 596.85K |
| Change in Working Capital | 644.43K | 1.27M | (665.75K) | 141.4K | 610.12K |
| Accounts Receivables | 184.26K | (78.6K) | 75.95K | (178.85K) | 46.59K |
| Inventory | 67.67K | (8.95K) | 26.91K | (32.5K) | (242.87K) |
| Accounts Payables | 319.23K | 1.11M | (387.9K) | (607.27K) | (457.58K) |
| Other Working Capital | 73.28K | 249.62K | (380.71K) | 960.02K | 1.26M |
| Other Non-Cash Items | 22.81K | 1.15M | 7.81M | 559.82K | 101.24K |
| Operating Cash Flow | (2.23M) | (2.3M) | (6.69M) | (6.1M) | (6.43M) |
| Capital Expenditures | (1.39K) | (61.21K) | (71.78K) | (27.78K) | (31.15K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (59.82K) | (41K) | 0 | (100K) |
| Investing Cash Flow | (1.39K) | (61.21K) | (71.78K) | (27.78K) | (131.15K) |
| Debt Repayment | 151.1K | 3.16M | 2.07M | 4.66M | (281.75K) |
| Common Stock Issued | 510K | 0 | 4.85M | 0 | 8.83M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (510K) | (866.74K) | (322.9K) | (168.32K) | (712.67K) |
| Financing Cash Flow | 661.1K | 2.29M | 6.59M | 9.74M | 7.83M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.57M) | (67.16K) | (175.14K) | 3.62M | 1.27M |
| Free Cash Flow | (2.24M) | (2.36M) | (6.77M) | (6.13M) | (6.46M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$7.8M
+ D&A$59.5K
+ Stock-Based Comp$596.9K
+ Deferred Tax$0
+ Working Capital$610.1K
+ Other Non-Cash$101.2K
= Operating Cash Flow-$6.4M
- Capex-$31.1K
= Free Cash Flow-$6.5M
Analysis
FY2025 free cash flow is -$6.5M. FCF conversion is 82.9% of net income. Operating cash flow was -$6.4M, with capex of -$31.1K. The largest bridge item is Working Capital at $610.1K.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Oct 14, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 8, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 8, 2026 |
Does NRXS generate free cash flow?
NeurAxis, Inc. (NRXS) generated -$6.46M of free cash flow in fiscal 2025.
How much operating cash flow does NRXS produce?
Operating cash flow was -$6.43M, before capital expenditures of $31,150.00.
Continue the stock analysis
Jump to another research area for this company.